This company listing is no longer active
Salud financiera de hoja de balance de Amryt Pharma
Salud financiera controles de criterios 4/6
Amryt Pharma has a total shareholder equity of $324.3M and total debt of $208.6M, which brings its debt-to-equity ratio to 64.3%. Its total assets and total liabilities are $736.9M and $412.6M respectively.
Información clave
64.3%
Ratio deuda-patrimonio
US$208.60m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$83.25m |
| Patrimonio | US$324.28m |
| Total pasivo | US$412.60m |
| Activos totales | US$736.88m |
Actualizaciones recientes sobre salud financiera
Recent updates
Análisis de la situación financiera
Pasivos a corto plazo: 3N9A's short term assets ($224.4M) exceed its short term liabilities ($143.1M).
Pasivo a largo plazo: 3N9A's short term assets ($224.4M) do not cover its long term liabilities ($269.5M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: 3N9A's net debt to equity ratio (38.7%) is considered satisfactory.
Reducción de la deuda: Insufficient data to determine if 3N9A's debt to equity ratio has reduced over the past 5 years.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: Whilst unprofitable 3N9A has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Pronóstico de cash runway: 3N9A is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 45.1% per year.